Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AS1801
- Development stage
- Unknown
- Lead developer
- Zhongke Aishen Pharmaceutical
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
AS1801 is a proprietary nucleic acid nano-delivery platform developed by **Zhongke Aishen Pharmaceutical** (also known as Amshenn). The technology is specifically engineered to enable the targeted delivery of nucleic acid therapeutics, such as siRNA or mRNA, to immune cells. By utilizing nanotechnology to overcome delivery barriers, AS1801 aims to modulate immune responses for the treatment of cancer and inflammatory diseases. As a platform technology, it serves as the foundation for multiple therapeutic programs within the company's pipeline, focusing on enhancing the precision and efficacy of immunotherapies while minimizing systemic off-target effects.
- Other names
- Nucleic acid nano-delivery platform
Beyond the preview
Go deeper on AS1801.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AS1801.